Pfizer wins FDA approval for Talzenna-Xtandi in earlier prostate cancer
Talzenna Xtandi FDA approval moves Pfizer's prostate cancer combination into earlier-stage treatment, backed by a 52% risk-reduction trial result.
Topic
prostate cancer
Every Financial News story tagged prostate cancer, newest first.
- Stories
- 1
- Last updated
- Follow
- RSS feed